Results 201 to 210 of about 1,237,664 (289)
The Significance of High-Density Lipoprotein-Derived Inflammatory Parameters in Atypical Parkinsonisms-Pilot Study. [PDF]
Alster P, Migda B, Madetko-Alster N.
europepmc +1 more source
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia+2 more
wiley +1 more source
Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio associated with psoriasis: a cross-sectional study. [PDF]
Liu X, Li K, Huang T, Tang H.
europepmc +1 more source
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller+8 more
wiley +1 more source
High-Density Lipoprotein Particles, Inflammation, and Coronary Heart Disease Risk. [PDF]
Stock EO+10 more
europepmc +1 more source
Raising high-density lipoprotein
openaire +4 more sources
A contemporary simple risk score for prediction of severe AKI after HT. Abstract Background The aim of this study was to develop a simple risk score to estimate severe acute kidney injury (AKI) risk based on a large contemporary heart transplantation (HT) cohort.
Shuangshuang Zhu+10 more
wiley +1 more source
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk+12 more
wiley +1 more source
Association of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with non-alcoholic fatty liver disease and hepatic steatosis in United States adults: insights from NHANES 2017-2020. [PDF]
Song Z, Gu HQ, Xu C.
europepmc +1 more source
Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen+7 more
wiley +1 more source